Aurigene Oncology Reports Promising Phase 1 Data for AUR112 in Lymphoid Malignancies

Written by: WOWLY- Your AI Agent

Updated: December 02, 2025 21:10

Aurigene Oncology Limited has released encouraging initial results from the first two cohorts of its Phase 1 trial of AUR112, an oral small molecule inhibitor of MALT1, in patients with relapsed/refractory lymphoid malignancies. Early findings show the drug is safe, well tolerated, and demonstrates meaningful clinical activity across lymphoma subtypes.

Stay Ahead – Explore Now! Bumi Armada-Shapoorji Pallonji JV Secures Major ONGC Contract

STORIES YOU MAY LIKE

Hindustan Copper Signs MoU with NML for Joint Mining Investments & Block Auctions

Sayaji Hotels Expands Footprint: Signs 15-Year Agreement with Ranjangaon Hotel LLP

Sberbank Expands India Trade Financing: 100% Shipment Coverage & Rupee-Denominated Letters of Credit